Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-1005 to Prevent Acute Noise Induced Hearing Loss
NCT02779192Phase 2Withdrawn
- Sponsor
- Sound Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ebselen in noise-induced hearing loss (NIHL), sponsored by Sound Pharmaceuticals. Planned start Jun 2026; status: withdrawn.
02
Drugs
ebselen
03
Conditions
noise-induced hearing loss (NIHL)
Beyond the preview
Go deeper on NCT02779192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779192.